Abstract:Background: The infarct size determines the long-term prognosis of patients with acute myocardial infarction (AMI). There is a growing interest in repairing scar area by transplanting bone marrow stem cells. However, effectiveness of intracoronary injection of bone marrow mesenchymal stem cells (BMSCs) in patients with AMI still remains unclear. Methods: Sixty-nine patients with AMI after percutaneous coronary intervention (PCI) were randomly divided into intracoronary injection of BMSCs (n = 34) and saline (control group, n = 35) groups. Serial single positron emission computer tomography (SPECT), cardiac echo and cardiac electromechanical mapping were done at the designed time intervals until six months after transplantation of BMSCs or injection of saline. Results: The proportion with functional defect decreased significantly in the BMSCs patients after three months [(13 +/- 5)%] compared with that pre-transplantation [(32 +/- 11)%] and the control group [(28 +/- 10)%] at three month follow-up (P < 0.05, respectively). Wall movement velocity over the infracted region increased significantly in the BMSCs group [(4.2 +/- 2.5) cm/s vs (2.2 +/- 1.3) cm/s, P < 0.05], but not in the control group [(2.2 +/- 1.5) cm/s vs (2.7 +/- 1.7) cm/s, P > 0.05]. Left ventricular ejection fraction (LVEF) three months after transplantation in BMSCs group increased significantly compared with that pre-implantation and with that of the control group at three months post-injection [(67 +/- 11)% vs (49 +/- 9)% and (53 +/- 8)%, P < 0.05 respectively]. SPECT scan results showed that perfusion defect was improved significantly in BMSCs group at three-month follow-up compared with that in the control group [(134 +/- 66) cm(2) vs (185 +/- 87) cm(2), P < 0.01]. At the same time, left ventricular end-diastolic volume [(136 +/- 31) ml vs (162 +/- 27) ml, P < 0.05] and end-systolic volume [(63 +/- 20) ml vs (88 +/- 19) ml, P < 0.05] decreased synchronously. The ratio of end-systolic pressure to end-systolic volume [Psyst/ESV, (2.84 +/- 1.30) mmHg/ml vs (1.72 +/- 1.23) mmHg/ml, P < 0.05] increased significantly. Cardiac electromechanical mapping demonstrated significant improvement at three months after implantation of BMSCs compared with that pre-injection in both cardiac mechanical capability as left line local shorting [LLS, (11.29 +/- 1.64)% vs (7.32 +/- 1.86)%, P < 0.05] and electrical property as left ventricular endocardial unipolar voltage [UV, (10.38 +/- 1.12) mV vs (7.61 +/- 1.09) mV, P < 0.01]; perfusion defect decreased from (36.2 +/- 6.2)% to (20.3 +/- 5.31)% (P < 0.01). Twenty-four-hour electrocardiographic monitoring demonstrated no arrhythmias occurred at three-months follow-up. Conclusions: The transplantation of BMSCs might improve the cardiac function and it is safe and feasible with no deaths or malignant arrhythmias.

Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST segment elevation myocardial infarction: A pilot study.

Transplantation of Autologous Endothelial Progenitor Cells May Be Beneficial in Patients with Idiopathic Pulmonary Arterial Hypertension: a Pilot Randomized Controlled Trial.

Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: Open-label pilot study

Thymosin Β4 Promotes Endothelial Progenitor Cell Angiogenesis Via a Vascular Endothelial Growth Factor‑dependent Mechanism.

Autologous Transplantation of Peripheral Blood Stem Cell in Treatment of Critical Limb Ischemia

Thymosin Β4 Promotes the Survival and Angiogenesis of Transplanted Endothelial Progenitor Cells in the Infarcted Myocardium

Therapeutic angiogenesis by transplantation of human embryonic stem cell-derived CD133+ endothelial progenitor cells for cardiac repair.

Safety and Efficacy of Intracoronary Hypoxia-Preconditioned Bone Marrow Mononuclear Cell Administration for Acute Myocardial Infarction Patients: the China-Ami Randomized Controlled Trial

[A Prospective, Randomized, Controlled Trial of Autologous Mesenchymal Stem Cells Transplantation for Dilated Cardiomyopathy].

Efficacy of Emergent Transcatheter Transplantation of Stem Cells for Treatment of Acute Myocardial Infarction (Tct-Stami)

Abstract 20556: Safety and Efficacy of Intracoronary Hypoxia-PrecondItioned Bone Marrow Mononuclear Cells Administration for Acute Myocardial Infarction Patients

Intravenous infusion of autologous endothelial progenitor cells in treatment of primary pulmonary hypertension

Transplantation of bone marrow-derived endothelial progenitor cells preconditioned with ex vivo 17β-estradiol enhances healing efficacy after acute myocardial infarction

Antiapoptotic Effect of Implanted Embryonic Stem Cell-Derived Early-Differentiated Cells in Aging Rats after Myocardial Infarction.

Autologous bone marrow mononuclear cell transplantation improves vascular endothelial function in patients with myocardial infarction and left ventricular dysfunction

Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction

[Intracoronary Transfer Autologous Bone Marrow Stem Cells Can Improve Cardiac Function in Patients with Left Ventricular Dysfunction after Myocardial Infarction].

Thymosin β4 increases cardiac cell proliferation, cell engraftment, and the reparative potency of human induced-pluripotent stem cell-derived cardiomyocytes in a porcine model of acute myocardial infarction

Treatment of myocardial infarction with autologous bone marrow stem cell transplantation

Long-term efficacy of emergent intracoronary transplantation of autologous bone marrow mononuclear cells for treatment of acute myocardial infarction

[Effects of Intracoronary Autologous Bone Marrow Mononuclear Cells Transplantation in Patients with Anterior Myocardial Infarction].